Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

CYP3A5 genotype has no impact on plasma trough concentrations of lopinavir and ritonavir in HIV-infected subjects.

Clinical pharmacology and therapeutics - 1 Aug 2008

Estrela R C E, Santoro A B, Barroso P F, Tuyama M, Suarez-Kurtz G

Abstract excerpt

CYP3A5 genotype has no impact on the trough plasma concentrations of lopinavir and ritonavir in human immunodeficiency virus (HIV)-infected individuals on stable highly active antiretroviral therapy (HAART). This is ascribed to a drug interaction, such that ritonavir by inhibiting CYP3A activity, may occlude the pharmacokinetic consequences of functional polymorphisms in the CYP3A5 gene. In the clinical setting,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anti-HIV Agents
Share to Antiretroviral Therapy, Highly Active

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cytochrome P-450 CYP3A

Share to Drug Therapy, Combination

Share to HIV Protease Inhibitors

Share to Lopinavir

Share to Pyrimidinones

Share to Ritonavir

Source

Identifiers

PMID: 18288082
DOI: 10.1038/clpt.2008.12

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

CYP3A5 genotype has no impact on plasma trough concentrations of lopinavir and ritonavir in HIV-infected subjects.PMID 18288082Read ↗

No influence of the P-glycoprotein genotype (MDR1 C3435T) on plasma levels of lopinavir and efavirenz during antiretroviral treatment.Semantic proximity Read ↗

The impact of SLCO1B1 polymorphisms on the plasma concentration of lopinavir and ritonavir in HIV-infected men.Semantic proximity Read ↗

CYP3A5 Genotype Impacts Maraviroc Concentrations in Healthy VolunteersSemantic proximity Read ↗

Analysis of single-nucleotide polymorphisms (SNPs) in human CYP3A4 and CYP3A5 genes: potential implications for the metabolism of HIV drugs.Semantic proximity Read ↗

Differences in genetic variants in lopinavir disposition among HIV-infected Bantu Africans.Semantic proximity Read ↗

No Clinical Impact of CYP3A5 Gene Polymorphisms on the Pharmacokinetics and/or Efficacy of Maraviroc in Healthy Volunteers and HIV-1-Infected Subjects.Semantic proximity Read ↗

CYP3A4*22 (c.522-191 C>T; rs35599367) is associated with lopinavir pharmacokinetics in HIV-positive adults.Semantic proximity Read ↗

ABCB1 polymorphisms and the concentrations of lopinavir and ritonavir in blood, semen and saliva of HIV-infected men under antiretroviral therapy.Semantic proximity Read ↗

CYP3A4 polymorphism and lopinavir toxicity in an HIV-infected pregnant woman.Semantic proximity Read ↗

CYP3A5, ABCB1, and SLCO1B1 polymorphisms and pharmacokinetics and virologic outcome of lopinavir/ritonavir in HIV-infected children.Semantic proximity Read ↗

CYP3A5 genotype has an impact on the metabolism of the HIV protease inhibitor saquinavir.Semantic proximity Read ↗

Clinical use of lopinavir/ritonavir in a salvage therapy setting: pharmacokinetics and pharmacodynamics.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.